Vol. 20/No. 23

During a recent OncLive Peer Exchange, a panel of leukemia and lymphoma experts discussed emerging BTK inhibitors.

The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

In an effort to expand treatment options for patients with recurrent HER2-positive breast cancer, investigators are testing a novel antibody-drug conjugate: [fam-] trastuzumab deruxtecan (DS-8201a). The drug has achieved breakthrough therapy status.

The proliferation of targeted therapies in non–small cell lung cancer has helped improve overall survival for patients with metastatic disease and illustrates the importance of molecular testing,

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Liquid biopsy technologies have made substantial headway in recent years, sparking booming commercial interest in the development of potential clinical applications.

Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology to issue its first guideline regarding radiation therapy in patients with pancreatic cancer.

Use of ibrutinib (Imbruvica) significantly increased the risk of early onset hypertension and was associated with long-term risk of developing other major cardiotoxic events in patients with B-cell malignancies.

Focusing on the needs of patients with cancer who were likely to be “superutilizers” of healthcare resources resulted in lower costs, fewer hospital admissions, and higher patient satisfaction scores for Crystal Run Healthcare.

Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that oncologists can keep pace with changes associated with the agency’s accelerated approval program.

When discussing the topic of vaccination to prevent serious childhood illness, an increasing number of individuals refuse to accept the unequivocally demonstrated value of this public health strategy despite the very low risk of harm.